U.S. Markets open in 4 hrs 11 mins
  • S&P Futures

    4,704.00
    +2.50 (+0.05%)
     
  • Dow Futures

    35,830.00
    +19.00 (+0.05%)
     
  • Nasdaq Futures

    16,494.75
    +13.50 (+0.08%)
     
  • Russell 2000 Futures

    2,365.40
    +1.20 (+0.05%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    56,971.74
    +2,653.22 (+4.88%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2020, and provided a corporate update. Recent highlights include:

  • Strong financial position:

    - Q1 2020 revenues of $4.3 million driven by NARCAN® Nasal Spray (“NARCAN®”) royalties of $4.2 million, an increase of 12 percent year-over-year
    - Projected royalties for the full-year 2020 of approximately $26.2 million, reiterated based on Emergent BioSolutions Inc. (“EBS”) revenue guidance for NARCAN®
    - Cash and cash equivalents of $32.2 million and no debt as of March 31, 2020

  • Update on submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for Opiant’s lead development program, OPNT003, nasal nalmefene, for opioid overdose:

    - FDA removed its clinical hold on OPNT003, allowing Opiant to proceed with pharmacokinetic (“PK”) study
    - Reached agreement with the FDA on the design of a pharmacodynamic (“PD”) study in healthy volunteers to support the OPNT003 NDA application
    - OPNT003 development program impacted by prolonged COVID-19 related travel restrictions on manufacturing equipment engineers in Europe
    - Opiant now expects to file an NDA in early 2021

  • Executed a cooperative research and development agreement with the National Center for Advancing Translational Sciences (“NCATS”) to formulate OPNT004 for human studies in Acute Cannabinoid Overdose

  • Paused initiation of recruitment for planned Phase 2 study of OPNT002 for Alcohol Use Disorder due to ongoing COVID-19 global health pandemic

“These results highlight our unique position: cash-strong, no debt, and with an increasing royalty stream from sales of NARCAN® supporting our robust pipeline across multiple compelling therapy areas in addiction and overdose,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “We also have the financial support and collaboration of multiple government agencies, including the National Institute on Drug Abuse (“NIDA”), NCATS, and the Biomedical Advanced Research and Development Authority (“BARDA”).”

Speaking about OPNT003, Dr. Crystal added: "We are pleased that the FDA has removed its clinical hold on OPNT003 for opioid overdose reversal. As we previously reported in January, the FDA placed our development of OPNT003 on hold as it reviewed certain characteristics of the intranasal delivery device. After reviewing our response, the FDA removed its clinical hold based on our agreement to amend slightly our PK study protocol. Therefore, we can move forward with our study as soon as feasible. Separately, we have agreed with the FDA on the design of a short PD study in healthy volunteers that we believe will enhance the clinical profile of OPNT003. As we progress towards our regulatory filing for OPNT003, we are also having to factor into our timeline the impact of prolonged COVID-19 related travel restrictions on our equipment engineers in Europe. Based on these collective modifications to our OPNT003 development program, our NDA filing is now likely to occur in early 2021.”

David O’Toole, Chief Financial Officer of Opiant, said: “We are well-positioned financially with significant cash, no debt and no need to access government programs in the United States or United Kingdom for COVID-19-related financial assistance or relief. Our pipeline investments and overall financial position continue to benefit from a resilient stream of revenue from the sales of NARCAN®.”

First quarter 2020 results

For the three months ended March 31, 2020, Opiant recorded approximately $4.3 million in revenue, compared to approximately $5.4 million during the corresponding period of 2019. The first quarter of 2019 included $1.7 million in revenue from the NIDA grant and the contract from BARDA. For the three months ended March 31, 2020, we recorded approximately $4.2 million of revenue from our license agreement with EBS for the sale of NARCAN®, compared to approximately $3.7 million in the same period of 2019. First-quarter 2020 sales of NARCAN® were approximately $72.2 million, as reported by EBS.

General and administrative expenses for the quarter were approximately $2.6 million, compared to approximately $3.4 million for the same period of 2019. The $0.8 million decrease is primarily attributable to a decrease in stock-based compensation and legal expenses.

Research and development expenses were approximately $1.4 million, as compared to approximately $3.6 million in the first three months of 2019. The $2.2 million decrease was primarily attributable to a reduction in third-party clinical trial and development expense.

Sales and marketing expenses were approximately $1.1 million, compared to none during the first three months in 2019. As Opiant continues to advance OPNT003 towards potential market approval, we anticipate that our sales and marketing expenses will increase in several areas to support the development of a commercial platform that would allow Opiant to potentially commercialize OPNT003, as well as future pipeline products.

Royalty expense for the first quarter was approximately $0.9 million due for payments to Net Profit Partners for the royalties received from the net sales of NARCAN®.

Net loss for the first quarter was approximately $1.7 million, or a loss of $0.40 per basic and diluted share, compared to a net loss of approximately $1.7 million, or a loss of $0.44 per basic and diluted share, for the comparable period of 2019.

As of March 31, 2020, Opiant had cash and cash equivalents of $32.2 million, compared to approximately $31 million at December 31, 2019. The current cash balance does not include the full impact of the NIDA grant of approximately $7.4 million or the BARDA contract of approximately $4.6 million.


Conference Call Details:

Tuesday, May 12th at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time

Toll Free:

877-407-0792

International:

201-689-8263

Conference ID:

13702897

Webcast:

http://public.viavid.com/index.php?id=139556


About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

For more information visit: www.opiant.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our filed quarterly reports on Form 10-Q and our annual report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 4, 2020, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Investor Relations Contacts:

Ben Atkins
VP of Corporate Communications and Investor Relations
Batkins@opiant.com
(310) 598-5410

Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 430-7576

Opiant Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except shares and per share amounts)

As of March 31,

As of December 31,

2020

2019

Assets

(unaudited)

Current Assets

Cash & cash Equivalents

$

32,198

$

30,981

Accounts receivable

4,205

7,218

Prepaid expenses and other current assets

1,023

1,056

Total Current Assets

37,426

39,255

Other assets

Property and equipment, net

199

243

Right of use assets - operating leases

628

769

Patents and patent applications, net

14

14

Total Assets

$

38,267

$

40,281

Liabilities and stockholders' equity

Current Liabilities

Accounts payable and accrued liabilities

$

1,450

$

1,317

Accrued salaries and wages

599

1,238

Royalty payable

934

1,620

Deferred revenue

843

918

Operating leases - current

500

517

Total Current Liabilities

4,326

5,610

Long-Term Liabilities

Operating leases - long term

131

255

Total Long-Term Liabilities

131

255

Total Liabilities

4,457

5,865

Stockholders' equity

Common stock, $0.001 par value, 200,000,000 shares

authorized, 3,925,361 and 3,845,361 shares

issued and outstanding at March 31, 2019

and December 31, 2018, respectively

4

4

Additional paid-in-capital

98,611

97,240

Foreign Currency Translation Adjustment

(293

)

-

Accumulated deficit

(64,512

)

(62,828

)

Total stockholders' equity

33,810

34,416

Total liabilities and stockholders' equity

$

38,267

$

40,281




Opiant Pharmaceuticals Inc.

Condensed Consolidated Statements of Operations

(in thousands, except shares and per share amounts)

Three months ended

Three months ended

March 31,

March 31,

2020

2019

(Unaudited)

(Unaudited)

Revenues

Royalty & licensing revenue

$

4,199

$

3,746

Treatment investment income

-

80

Grant and contract revenue

84

1,609

Total Revenue

4,283

5,435

Operating Expenses

General and administrative

2,573

3,382

Research and development

1,421

3,567

Sales & marketing

1,077

-

Royalty expense

934

314

Total expenses

6,005

7,263

Loss from operations

(1,722

)

(1,828

)

Other income (expense)

Interest income, net

76

122

Loss on foreign exchange

-

(30

)

Total other income (expense)

76

92

Loss before provision for income taxes

(1,646

)

(1,736

)

Income tax expense

(39

)

-

Net loss

$

(1,685

)

$

(1,736

)

Other comprehensive loss:

Foreign currency translation loss adjustment

(293

)

-

Comprehensive loss

$

(1,978

)

$

(1,736

)

Net loss per common share

Basic & Diluted

$

(0.40

)

$

(0.44

)

Weighted-average common shares outstanding:

Basic & Diluted

4,224,555

3,909,702